China Authorizes Gotistobart for Breakthrough Therapy against Aggressive Lung Cancer OncoC4 announces that China's NMPA has granted Breakthrough Therapy Designation for Gotistobart (BNT316/ONC-392) aimed at treating squamous non-small cell lung cancer, enhancing prospects for patients facing limited options.

China Authorizes Gotistobart for Breakthrough Therapy against Aggressive Lung Cancer #China #Rockville #OncoC4 #Gotistobart #BNT316